Current Report Filing (8-k)
April 14 2021 - 06:07AM
Edgar (US Regulatory)
0000727207
false
0000727207
2021-04-09
2021-04-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of report
(Date of earliest event reported)
|
April 9, 2021
|
Accelerate Diagnostics, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction
of incorporation)
001-31822
|
|
84-1072256
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
3950 South Country Club Road, Suite 470, Tucson, Arizona
|
|
85714
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(520) 365-3100
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
AXDX
|
The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
As previously announced, on December 24, 2020,
Accelerate Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase
Agreement”) with certain purchasers (collectively, the “Purchasers”) for the issuance and sale by the Company of an
aggregate of 4,166,663 shares of the Company’s common stock (the “Shares”) to the Purchasers in an offering (the “Private
Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated
thereunder. The Purchasers are comprised of certain directors and officers of the Company, or entities affiliated or related to such persons.
The closing of the purchase and sale of the Shares
is expected to occur in three approximately equal tranches, with the first tranche having closed on February 19, 2021. On April 9,
2021, the Company closed the second tranche of the Private Placement and issued to the Purchasers an aggregate of 1,388,886 Shares for
proceeds of approximately $10.7 million.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ACCELERATE DIAGNOSTICS, INC.
|
|
(Registrant)
|
Date: April 14, 2021
|
|
|
/s/ Steve Reichling
|
|
Steve Reichling
|
|
Chief Financial Officer
|
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2023 to Mar 2024